United States Active Pharmaceutical Ingredient Market to 2026 by Method of Synthesis, Source, Distribution Channel, Therapeutic Application, Form, Molecule, Potency, Drug Type, Region

DUBLIN, March 8, 2021 /PRNewswire/ -- The "United States Active Pharmaceutical Ingredient Market, By Method of Synthesis, By Source, By Distribution Channel, By Therapeutic Application, By Form, By Molecule Type, By Potency, By Drug Type, By Region, Competition Forecast & Opportunities, 2016 - 2026" report has been added to ResearchAndMarkets.com's offering.

The United States Active Pharmaceutical Ingredient Market stood at USD17.81 billion in 2020 and is projected to grow at a CAGR of 9.73% to cross USD31.48 billion by 2026.

This can be attributed to growing prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer, respiratory disorders, among others. This has drastically increased the patient pool thereby increasing the demand for drugs. This in turn is expected to positively influence the market growth through 2026.

Additionally, increasing R&D by various biopharmaceutical companies in drug discovery is further expected to spur the market growth over the next few years. Besides this, growing importance of generics is also expected to foster the market growth in the next five years.

The United States Active Pharmaceutical Ingredient Market can be segregated based on method of synthesis, source, distribution channel, therapeutic application, form, molecule type, potency, drug type, region and company. Based on method of synthesis, the market can be split into synthetic and biological.

The synthetic method of synthesis dominated the market with a share of 58.29% in 2020 on account of the easy availability of raw materials and easier process for development of active pharmaceutical ingredients. While the biological method of synthesis segment is expected to grow at a rate of 10.82% during the forecast period owing to the growing demand for vaccines, monoclonal antibodies, recombinant proteins, biosimilars, among others.

Leading players operating in the market include Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Pfizer Inc., Dr. Reddy's Laboratories Limited, Lupin Pharmaceuticals, Inc., Glenmark Pharmaceuticals, Inc., GlaxoSmithKline Plc, Novartis Inc. (Sandoz), Aurobindo Pharma USA, Inc., Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Sanofi-Aventis U.S. LLC and others.

Major companies are developing advanced technologies and launching new products to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments. For instance, in 2020, Pfizer (US) signed a multiyear agreement with Gilead Sciences Inc., to manufacture and supply Gilead's antiviral drug (Remdesivir) for the treatment of COVID-19.

Key Target Audience:

• Active pharmaceutical ingredient manufacturers, contract manufacturers and other stakeholders
• Market research and consulting firms
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to active pharmaceutical ingredient

Years considered for this report:

• Historical Years: 2016 - 2019
• Base Year: 2020
• Estimated Year: 2021
• Forecast Period: 2022- 2026

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on United States Active Pharmaceutical Ingredient Market

4. Executive Summary

5. Global Active Pharmaceutical Ingredient Market Outlook

6. United States Active Pharmaceutical Ingredient Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Method of Synthesis (Biological v/s. Synthetic)
6.2.2. By Source (In-house v/s Contract Manufacturing Organizations)
6.2.3. By Distribution Channel (Online v/s Offline)
6.2.4. By Therapeutic Application (Cardiovascular Disease, Anti-diabetic, Oncology, Neurological Disorders, Musculoskeletal, Others)
6.2.5. By Form (Tablet, Capsule, Injection, Others)
6.2.6. By Molecule Type (Small v/s Large)
6.2.7. By Potency (High v/s Low)
6.2.8. By Drug Type (Innovator v/s Generic)
6.2.9. By Region (West, Mid-West, North-East, South)
6.2.10. By Company
6.3. Product Market Map

7. United States Biological Active Pharmaceutical Ingredient Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type (Recombinant Proteins, Vaccines, Monoclonal Antibodies, Hormones, Others)
7.2.2. By Therapeutic Application
7.2.3. By Source
7.2.4. By Distribution Channel
7.2.5. By Form
7.2.6. By Molecule Type
7.2.7. By Potency
7.2.8. By Drug Type

8. United States Synthetic Active Pharmaceutical Ingredient Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type (Inorganic Synthetic Drugs vs. Organic Synthetic Drugs)
8.2.2. By Therapeutic Application
8.2.3. By Source
8.2.4. By Distribution Channel
8.2.5. By Form
8.2.6. By Molecule Type
8.2.7. By Potency
8.2.8. By Drug Type

9. Market Dynamics
9.1. Drivers
9.2. Challenges

10. Market Trends & Developments

11. Trade Dynamics (Top 5 APIs)
11.1. Export
11.2. Import

12. Policy & Regulatory Landscape

13. United States Economic Profile

14. Competitive Landscape (SWOT Analysis of Top 5 Players)
14.1. Competition Outlook
14.2. Company Profiles
14.2.1. Teva Pharmaceutical Industries Limited
14.2.2. Merck & Co., Inc.
14.2.3. Pfizer Inc.
14.2.4. Dr. Reddy's Laboratories Limited
14.2.5. Lupin Pharmaceuticals, Inc.
14.2.6. Glenmark Pharmaceuticals, Inc.
14.2.7. GlaxoSmithKline Plc
14.2.8. Novartis Inc. (Sandoz)
14.2.9. Aurobindo Pharma USA, Inc.
14.2.10. Sun Pharmaceutical Industries Ltd.
14.2.11. Eli Lilly and Company
14.2.12. AbbVie Inc.
14.2.13. Bristol-Myers Squibb
14.2.14. F. Hoffmann-La Roche Ltd.
14.2.15. Sanofi-Aventis U.S. LLC

15. Strategic Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/mcfdgh

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets